Singapore markets closed

Takeda Pharmaceutical Company Limited (TAK)

NYSE - Nasdaq Real-time price. Currency in USD
Add to watchlist
13.84+0.11 (+0.80%)
At close: 04:00PM EDT
13.50 -0.34 (-2.46%)
After hours: 07:59PM EDT

Takeda Pharmaceutical Company Limited

1-1, Nihonbashi-Honcho 2-chome
Tokyo 103-8668
81 3 3278 2111

IndustryDrug Manufacturers—Specialty & Generic
Full-time employees47,099

Key executives

NameTitlePayExercisedYear born
Mr. Christophe WeberPres, CEO & Representative Director11.63MN/A1966
Mr. Constantine SaroukosCFO & Representative Director4.2MN/A1971
Mr. Yasuhiko YamanakaAdvisor295.49kN/A1956
Dr. Andrew S. PlumpPres of R&D and Representative Director5.98MN/A1965
Dr. Seigo IzumoChair of Management BoardN/AN/AN/A
Mr. Haruhiko HirateMember of Management BoardN/AN/A1957
Salvatore AlesciMember of Management Board and Head of R&D Global Science & Biomedical PolicyN/AN/AN/A
Norimasa TakedaChief Accounting Officer & Corp. ControllerN/AN/AN/A
Mr. Iwaaki TaniguchiSr. VP of Corp. Fin. & Controlling DepartmentN/AN/AN/A
Mr. Gabriele RicciChief Data & Technology OfficerN/AN/AN/A
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Takeda Pharmaceutical Company Limited engages in the research, development, manufacturing, marketing, and out-licensing of pharmaceutical products worldwide. It offers pharmaceutical products in the areas of gastroenterology; oncology; neuroscience; and rare diseases, such as rare metabolic and hematology, and heredity angioedema, as well as plasma-derived therapies and vaccines. The company provides its products under the Entyvio, Gattex/Revestive, Alofisel, Natpara, Adynovate/Adynovi, Takhzyro, Elaprase, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Albumin/Flexbumin, Ninlaro, and Alunbrig brands. Takeda Pharmaceutical Company has licensing agreements with Denali Therapeutics and Wave Life Sciences Ltd; collaboration agreements with Neurocrine Biosciences, Inc. and Rani Therapeutics LLC; license and research agreements with The University of Texas MD Anderson Cancer Center, Poseida Therapeutics, Inc., and Arrowhead Pharmaceuticals Inc.; research collaboration agreements with Arrowhead Pharmaceuticals Inc. and Ovid Therapeutics Inc.; and collaboration with Evox Therapeutics Ltd., as well as a licensing agreement with ProThera Biologics Inc. It also has strategic alliances with Egle Therapeutics SAS; Evotec SE; Neurocrine Biosciences, Inc.; Carmine Therapeutics; HemoShear Therapeutics, LLC; KSQ Therapeutics; and Anima Biotech. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.

Corporate governance

Takeda Pharmaceutical Company Limited’s ISS governance QualityScore as of 1 May 2022 is 1. The pillar scores are Audit: 1; Board: 1; Shareholder rights: 9; Compensation: 1.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.